These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3345396)

  • 1. Assessment of opioid dependence with naloxone.
    Peachey JE; Lei H
    Br J Addict; 1988 Feb; 83(2):193-201. PubMed ID: 3345396
    [No Abstract]   [Full Text] [Related]  

  • 2. Naloxone applied to conjunctiva as a test for physical opiate dependence.
    Creighton FJ; Ghodse AH
    Lancet; 1989 Apr; 1(8641):748-50. PubMed ID: 2564564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mydriatic response to topical naloxone in opiate abusers.
    Ghodse AH; Bewley TH; Kearney MK; Smith SE
    Br J Psychiatry; 1986 Jan; 148():44-6. PubMed ID: 3955319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 7. Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria.
    Kosten TA; Jacobsen LK; Kosten TR
    Am J Drug Alcohol Abuse; 1989; 15(3):237-50. PubMed ID: 2763981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ophthalmic naloxone elicits abstinence in opioid-dependent subjects.
    Sanchez-Ramos JR; Senay EC
    Br J Addict; 1987 Mar; 82(3):313-5. PubMed ID: 3471262
    [No Abstract]   [Full Text] [Related]  

  • 9. The acceptability of combined methadone-naloxone treatment: Consumer and provider views on the potential utility of methadone-naloxone.
    Shearer J; Mammen K; Bell J
    Drug Alcohol Rev; 2010 Mar; 29(2):138-43. PubMed ID: 20447220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use predicts treatment outcome, not opiate dependence or withdrawal.
    Kosten TA; Bianchi MS; Kosten TR
    NIDA Res Monogr; 1989; 95():459-60. PubMed ID: 2641030
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
    Wright C; Bigelow GE; Stitzer ML
    NIDA Res Monogr; 1989; 95():395-6. PubMed ID: 2701308
    [No Abstract]   [Full Text] [Related]  

  • 12. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use-buprenorphine/naloxone treatment and recovery in a surgical patient.
    Conroy S; Hill D
    BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25519865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
    Stitzer ML; Wright C; Bigelow GE; June HL; Felch LJ
    Drug Alcohol Depend; 1991 Dec; 29(1):39-46. PubMed ID: 1665778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1983 perspectives on the pharmacotherapy of opiate addiction.
    Cushman P
    Drug Alcohol Depend; 1983 Feb; 11(1):87-93. PubMed ID: 6851863
    [No Abstract]   [Full Text] [Related]  

  • 17. Orally delivered methadone as a reinforcer: Effects of the opioid antagonist naloxone.
    Wang NS; Stewart RB; Meisch RA
    Drug Alcohol Depend; 1999 Jun; 55(1-2):79-84. PubMed ID: 10402152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
    Schottenfeld RS; Chawarski MC; Pakes JR; Pantalon MV; Carroll KM; Kosten TR
    Am J Psychiatry; 2005 Feb; 162(2):340-9. PubMed ID: 15677600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone challenge as a biological predictor of treatment outcome in opiate addicts.
    Jacobsen LK; Kosten TR
    Am J Drug Alcohol Abuse; 1989; 15(4):355-66. PubMed ID: 2596440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.